recently come under the radar as a potential new biomarker for HF – one that is more cost-effective, less invasive, more convenient and acceptable for both patients and healthcare professionals, and one which could potentially reflect the information received from a standard blood NTproBNP test. One hurdle in measuring NTproBNP in saliva samples using standard point-of-care (POC) devices is the level of this protein in saliva. Measuring about 2000-fold lower, saliva NTproBNP is hardly measurable with standard POC devices. Here we present the KardiaTool platform, an integrated POC solution for non-invasive diagnosis and therapy monitoring of HF patients. The platform consists of two components, KardiaPOC (a highly sensitive portable device for non-invasive and simultaneous quantitative assessment of multiple HF related biomarkers from saliva samples, incorporating a functionalized magnetic nanoparticle approach) and KardiaSoft (a decision support software based on predictive modelling techniques that analyses POC and other patient data, and delivers information on HF diagnosis and therapy monitoring). The KardiaTool platform was developed as part of an ongoing collaborative Horizon 2020 project, KARDIATOOOL.

Methods and Results The aim of this sub-study was to test the hypothesis that saliva NTproBNP levels correlate to blood NTproBNP levels. To achieve this, we recruited chronic heart failure patients attending the HF unit in St. Michael’s Hospital (SVUH, Dublin). Patients underwent routine physical examination, including venepuncture, echocardiography and electrocardiography. NTproBNP was quantified in peripheral blood samples. Saliva was collected with the SalivaBio Oral Swab device and extracted following centrifugation at 5000 g for 5 min. Saliva samples were assessed with a modified immunoassay prior to the official KardiaPOC testing. Results from the first 46 HF patients show a significant and positive correlation between blood and saliva NTproBNP (p<0.05). In addition, saliva NTproBNP correlated significantly with echocardiography parameters, including LA diameter (r=0.36, p=0.02) and E/A ratio (r=0.43, p=0.01).

Conclusions We were successfully able to quantify saliva NTproBNP levels in HF patients using a modified immunoassay approach, and these levels correlated with blood levels. The KardiaTool project is still ongoing, with patient recruitment in Ireland, Greece, and Italy. The next stage is to test the KardiaPOC device, which we envisage will have superior sensitivity for saliva NTproBNP quantification, and to determine the diagnostic test accuracy for acute and chronic heart failure.

NOVEL HEART FAILURE BIOMARKER CLEC3B IS ASSOCIATED WITH CARDIAC FIBROSIS, AND IMPACTS CARDIAC FIBROBLAST CELL FUNCTION IN VITRO

1K Edgar, 1C Tony, 2B Collins, 3C Moravec, 4M Ledwidge, 5K McDonald, 6P Collier, 7D Grieve, 8C Watson. 1Welcome-Wolfson Institute for Experimental Medicine, Queens University Belfast, UK; 2School of Biological Sciences, Queen’s University Belfast, UK; 3Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Ohio, USA; 4Heartbeat Trust, Dublin, Ireland; 5St. Vincent’s University Hospital, Dublin, Ireland; 6Cleveland Clinic, USA; 7Queen’s University Belfast, UK

Background As recent evidence has emerged indicating the efficacy of sodium-glucose-co-transporter-2 inhibitors (SGLT2i) in reducing all-cause mortality as well as hospitalisations in patients with HFrEF, it has been widely and quickly adapted into Cardiology practice. However, given the comorbidities and polypharmacy associated with this patient cohort, the real-world initiation and monitoring can be challenging.

Aim To assess the renal biochemical effects of SGLT2i initiation, as well as effects on hospitalisation and side effects in a